Published on May 9, 2016

The Indian Pharma market is scrappy with about 24,000 players. The market is dominated majorly by branded generics, which constitutes nearly 70% to 80% of market. 

Presently the government has been taking cost effective actions to reduce healthcare expenses. Thus, governments are focusing on speedy introduction of generic drugs into the market.

For the US market, Indian companies are developing niche portfolios in various segments. High margin injectables, dermatology, respiratory, biosimilars, complex generics etc. have become an area of interest. Currently most of the Indian pharma companies have been working on these niche drugs to optimize growth and margins.

Some market players have said that domestic pharmaceutical industry has not approached the government for early intervention to resolve regulatory issues faced by them in the US. Indian pharmaceutical exports to the US have increased from USD 3.4 billion in 2013-14 to USD 3.8 billion in 2014-15.

As per the recent report, to protect domestic manufacturers, India is planning to impose anti-dumping duty of up to $279.78 per tonne on imports of a chemical used by pharma, agro and fragrance industries from China and Russia. Apart from this, the government is taking a number of initiatives to help pharma firms upgrade technology and promote drug discovery and innovation in the country which will enhance the growth of the industry.